Literature DB >> 35973424

Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment.

Peng Zhang1, Zhimin Chen1, Henry Kuang1, Tongyu Liu1, Jiaqiang Zhu2, Linkang Zhou1, Qiuyu Wang1, Xuelian Xiong1, Ziyi Meng1, Xiaoxue Qiu1, Ramiah Jacks3, Lu Liu4, Siming Li1, Carey N Lumeng3, Qing Li4, Xiang Zhou5, Jiandie D Lin6.   

Abstract

The mammalian liver comprises heterogeneous cell types within its tissue microenvironment that undergo pathophysiological reprogramming in disease states, such as non-alcoholic steatohepatitis (NASH). Patients with NASH are at an increased risk for the development of hepatocellular carcinoma (HCC). However, the molecular and cellular nature of liver microenvironment remodeling that links NASH to liver carcinogenesis remains obscure. Here, we show that diet-induced NASH is characterized by the induction of tumor-associated macrophage (TAM)-like macrophages and exhaustion of cytotoxic CD8+ T cells in the liver. The adipocyte-derived endocrine factor Neuregulin 4 (NRG4) serves as a hormonal checkpoint that restrains this pathological reprogramming during NASH. NRG4 deficiency exacerbated the induction of tumor-prone liver immune microenvironment and NASH-related HCC, whereas transgenic NRG4 overexpression elicited protective effects in mice. In a therapeutic setting, recombinant NRG4-Fc fusion protein exhibited remarkable potency in suppressing HCC and prolonged survival in the treated mice. These findings pave the way for therapeutic intervention of liver cancer by targeting the NRG4 hormonal checkpoint.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HCC; NASH; NRG4; T cell; adipokine; endocrine; fatty liver disease; liver cancer; macrophage; microenvironment; single-cell RNA-seq

Mesh:

Substances:

Year:  2022        PMID: 35973424      PMCID: PMC9458631          DOI: 10.1016/j.cmet.2022.07.010

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   31.373


  78 in total

Review 1.  Nonalcoholic Steatohepatitis.

Authors:  Ayako Suzuki; Anna Mae Diehl
Journal:  Annu Rev Med       Date:  2016-10-05       Impact factor: 13.739

Review 2.  Macrophage heterogeneity in liver injury and fibrosis.

Authors:  Frank Tacke; Henning W Zimmermann
Journal:  J Hepatol       Date:  2014-01-08       Impact factor: 25.083

3.  Decreased serum neuregulin 4 levels associated with non-alcoholic fatty liver disease in children with obesity.

Authors:  Ran Wang; Fan Yang; Li Qing; Rong Huang; Qianqi Liu; Xiaonan Li
Journal:  Clin Obes       Date:  2018-11-08

4.  ERBB4 acts as a suppressor in the development of hepatocellular carcinoma.

Authors:  Yao Liu; Liming Song; Hengli Ni; Lina Sun; Weijuan Jiao; Lin Chen; Qun Zhou; Tong Shen; Hongxia Cui; Tianming Gao; Jianming Li
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

Review 5.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

6.  Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.

Authors:  Bashar Mohamad; Vaishal Shah; Mykola Onyshchenko; Mohammed Elshamy; Federico Aucejo; Rocio Lopez; Ibrahim A Hanouneh; Razan Alhaddad; Naim Alkhouri
Journal:  Hepatol Int       Date:  2015-11-11       Impact factor: 6.047

Review 7.  Spatial heterogeneity in the mammalian liver.

Authors:  Shani Ben-Moshe; Shalev Itzkovitz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

8.  Heterogeneity of HSCs in a Mouse Model of NASH.

Authors:  Sara Brin Rosenthal; Xiao Liu; Souradipta Ganguly; Debanjan Dhar; Martina P Pasillas; Eugenia Ricciardelli; Rick Z Li; Ty D Troutman; Tatiana Kisseleva; Christopher K Glass; David A Brenner
Journal:  Hepatology       Date:  2021-08-10       Impact factor: 17.425

9.  C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation.

Authors:  Roberta Bulla; Claudio Tripodo; Damiano Rami; Guang Sheng Ling; Chiara Agostinis; Carla Guarnotta; Sonia Zorzet; Paolo Durigutto; Marina Botto; Francesco Tedesco
Journal:  Nat Commun       Date:  2016-02-01       Impact factor: 14.919

10.  Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression.

Authors:  Liang Guo; Peng Zhang; Zhimin Chen; Houjun Xia; Siming Li; Yanqiao Zhang; Sune Kobberup; Weiping Zou; Jiandie D Lin
Journal:  J Clin Invest       Date:  2017-11-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.